<DOC>
	<DOC>NCT00603538</DOC>
	<brief_summary>Investigate safety, tolerability and pharmacokinetics of CP-751,871 when given in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer</brief_summary>
	<brief_title>Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Diagnosis of advanced nonsmall cell lung cancer Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Any prior treatment for nonsmall cell lung cancer Brain metastases With diabetes</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>CP-751,871, Non-small cell lung cancer, Phase 1</keyword>
</DOC>